World's Best Scientists 2026 revealed!
Hans-Juergen Woerle

Hans-Juergen Woerle

D-Index & Metrics

Medicine

D-Index
88
Citations
43599
World Ranking
12928
National Ranking
180

Overview

Hans-Juergen Woerle is affiliated with Nestlé (Switzerland) based in Switzerland. Their research primarily focuses on medicine, with specific concentration in the subfields of endocrinology, diabetes, and metabolism, as well as surgery.

The scientific topics addressed in their work include diabetes treatment and management, pancreatic function and diabetes, and diabetes management and research.

Woerle's recent publication record includes the paper titled "Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?" published in 2020 in the journal Diabetes Obesity and Metabolism.

  • Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels? (2020, Diabetes Obesity and Metabolism)

Their frequent co-authors include:

  • Ruth L. Coleman
  • Alastair Gray
  • Uli C. Broedl
  • David Fitchett
  • Jyothis T. George

Woerle's publications have appeared in venues such as Diabetes Obesity and Metabolism, reflecting their specialized interest in diabetes and metabolic disorders.

Best Publications

  • Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

    Bernard Zinman;Christoph Wanner;John M. Lachin;David Fitchett

  • Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

    David Z.I. Cherney;Bruce A. Perkins;Nima Soleymanlou;Maria Maione

  • Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

    Ele Ferrannini;Elza Muscelli;Silvia Frascerra;Simona Baldi

  • Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

    Julio Rosenstock;Vlado Perkovic;Odd Erik Johansen;Mark E. Cooper

  • Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial

    David Fitchett;Bernard Zinman;Bernard Zinman;Christoph Wanner;John M. Lachin

  • Renal Gluconeogenesis Its importance in human glucose homeostasis

    John E. Gerich;Christian Meyer;Hans J. Woerle;Michael Stumvoll

  • Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

    Anthony H Barnett;Ambrish Mithal;Jenny Manassie;Russell Jones

  • Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.

    Julio Rosenstock;Steven E. Kahn;Odd Erik Johansen;Bernard Zinman;Bernard Zinman

  • Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes

    Robert J Chilton;I. Tikkanen;C. P. Cannon;S. Crowe

  • Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

    Michael Roden;Jianping Weng;Jens Eilbracht;Bruno Delafont

  • Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension

    Ilkka Tikkanen;Kirsi Narko;Cordula Zeller;Alexandra Green

  • SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials

    Silvio E Inzucchi;Bernard Zinman;Christoph Wanner;Roberto Ferrari

  • The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.

    David Zi Cherney;Bruce A Perkins;Nima Soleymanlou;Ronnie Har

  • Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease

    Christoph Wanner;John M. Lachin;Silvio E. Inzucchi;David Fitchett

  • 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.

    Baptist Gallwitz;Julio Rosenstock;Thomas Rauch;Sudipta Bhattacharya

  • Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.

    C. S. Kovacs;V. Seshiah;R. Swallow;R. Jones

  • Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

    Hans-Ulrich Häring;Ludwig Merker;Elke Seewaldt-Becker;Marc Weimer

  • Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.

    Hans-Ulrich Häring;Ludwig Merker;Elke Seewaldt-Becker;Marc Weimer

  • Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes

    Julio Rosenstock;Ante Jelaska;Guillaume Frappin;Afshin Salsali

  • Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

    S. Del Prato;A. H. Barnett;H. Huisman;D. Neubacher

Frequent Co-Authors

Bernard Zinman
Bernard Zinman University of Toronto
Silvio E. Inzucchi
Silvio E. Inzucchi Yale University
John E. Gerich
John E. Gerich Mayo Clinic
Julio Rosenstock
Julio Rosenstock The University of Texas Southwestern Medical Center
Christoph Wanner
Christoph Wanner University of Würzburg
John M. Lachin
John M. Lachin George Washington University
Anthony H. Barnett
Anthony H. Barnett University of Birmingham
Per-Henrik Groop
Per-Henrik Groop University of Helsinki
Mark E. Cooper
Mark E. Cooper Monash University
Darren K. McGuire
Darren K. McGuire The University of Texas Southwestern Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a medical career in the USA opens many doors beyond a traditional MD. Many students choose alternative healthcare pathways that can be pursued through flexible online degrees. For those drawn to patient care, a nursing degree online provides an accessible route into the field, especially for those managing work and study.

If you are already working as a registered nurse and want to enhance your qualifications, affordable rn to bsn programs help nurses advance their careers and qualify for leadership roles. For those interested in research or teaching, there are phd nursing programs online with flexible schedules and lower costs.

Not a nurse yet? Non-nurses with a bachelor’s degree can explore direct entry np programs for non nurses online, which fast-track graduates into advanced nursing practice. Each pathway offers unique opportunities to enter or progress in the US healthcare sector, making online study an increasingly popular and practical choice.

Best Scientists Citing Hans-Juergen Woerle

Trending Scientists